Want To Bet On Ozempic, Wegovy Success? Defiance Introduces Leveraged ETF To Capture Novo Nordisk Momentum

On Tuesday, Defiance ETFs introduced NVOX, the first single-stock leveraged ETF focused on Danish pharmaceutical giant Novo Nordisk A/S NVO.

The ETF offers retail investors double the daily long exposure to Novo Nordisk's stock price changes without requiring a margin account, presenting an innovative trading option.

However, NVOX carries heightened risk due to its single-stock nature and does not invest directly in Novo Nordisk shares.

Also Read: Big Pharma Pushes To Revise Biden-era Medicare Drug Price Negotiation Law Under Trump

Sylvia Jablonski, CEO of Defiance ETFs, emphasized the strategic importance of NVOX, highlighting Novo Nordisk's central role in the booming weight loss market.

The company produces the popular drugs Ozempic and Wegovy, which have positioned it as a key player in an industry with significant growth potential.

Novo Nordisk reported that in the third quarter of 2024, Wegovy sales reached 17.30 billion Danish kroner, up 81%, and Ozempic sales increased 26% at constant currency to 29.80 billion Danish kroner.

Jablonski described NVOX as a tool for investors looking to capitalize on this multi-trillion-dollar opportunity.

Established in 2018, Defiance ETFs specializes in income and thematic investing, offering products tailored for tactical trading opportunities. Its suite of ETFs spans disruptive technologies such as artificial intelligence and quantum computing.

In August, Defiance ETFs introduced LLYX the Defiance Daily Target 2X Long LLY ETF, which seeks daily leveraged investment results of two times (200%) the daily percentage change in the share price of Eli Lilly And Co LLY.

According to research published in JAMA Network Open, the use of anti-obesity medications, including glucagon-like peptide-1 receptor agonists, was associated with lower incidence and recurrence of alcohol use disorder.

Price Action: NVO stock is up 2.02% at $110.86 during the premarket session at last check Tuesday.

Read Next:

• PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program

Photo via Shutterstock